Acute pancreatitis associated with boceprevir: a case report.
Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30-50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy, but it is associated with an increased incidence of adverse events. We herein report a case of acute pancreatitis developed during treatment with pegylated interferon, ribavirin and boceprevir. Boceprevir was the most likely cause of drug-associated pancreatitis after the most common causes were ruled out, since this adverse event had not occurred when the patient had previously been exposed to pegylated interferon and ribavirin and there was no recurrence of the episode of pancreatitis when these two drugs were reintroduced. Acute pancreatitis is a rare adverse event associated with boceprevir therapy, but a potentially fatal event. Sequential determination of pancreatic enzymes should be considered during hepatitis C treatment with boceprevir.
Universidade Federal de São Paulo (UNIFESP)São Paulo, SP, Brazil. Electronic address: jmbilar@gmail.com.
Juliana Miguel
JM
Bilar
Universidade Federal de São Paulo (UNIFESP)São Paulo, SP, Brazil.
Roberto José
RJ
Carvalho-Filho
Universidade Federal de São Paulo (UNIFESP)São Paulo, SP, Brazil.
Carolina Frade Magalhães Girardin Pimentel
CF
Mota
Universidade Federal de São Paulo (UNIFESP)São Paulo, SP, Brazil.
Patricia da Silva
Pda S
Fucuta
Universidade Federal de São Paulo (UNIFESP)São Paulo, SP, Brazil.
Maria Lucia Cardoso Gomes
ML
Ferraz
D000208:Acute Disease; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D010195:Pancreatitis / Q000139:chemically induced* / Q000175:diagnosis; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011392:Proline / Q000009:adverse effects / Q000031:analogs & derivatives*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; C100416:peginterferon alfa-2a
Hepatitis C; Protease inhibitor; Side effect